A carregar...
Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
Tepotinib is a key drug for cancer patients with mesenchymal‐epithelial transition receptor tyrosine kinase proto‐oncogene (MET) exon 14 skipping mutation. However, its bioavailability in the cerebrospinal fluid (CSF) in humans has not been fully elucidated. Moreover, information about the efficacy...
Na minha lista:
| Publicado no: | Cancer Commun (Lond) |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7819565/ https://ncbi.nlm.nih.gov/pubmed/33387444 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cac2.12124 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|